[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2017000984A1 - Reducción de la viscosidad de formulaciones farmacéuticas - Google Patents

Reducción de la viscosidad de formulaciones farmacéuticas

Info

Publication number
CL2017000984A1
CL2017000984A1 CL2017000984A CL2017000984A CL2017000984A1 CL 2017000984 A1 CL2017000984 A1 CL 2017000984A1 CL 2017000984 A CL2017000984 A CL 2017000984A CL 2017000984 A CL2017000984 A CL 2017000984A CL 2017000984 A1 CL2017000984 A1 CL 2017000984A1
Authority
CL
Chile
Prior art keywords
viscosity
reduction
pharmaceutical formulations
pharmaceutical formulation
lylin
Prior art date
Application number
CL2017000984A
Other languages
English (en)
Inventor
Christopher James Sloey
Sekhar Kanapuram
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000984(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CL2017000984A1 publication Critical patent/CL2017000984A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>SE PROPORCIONA UN MÉTODO PARA REDUCIR LA VISCOSIDAD DE UNA FORMULACIÓN FARMACÉUTICA QUE UTILIZA UNA CONCENTRACIÓN DE REDUCCIÓN DE LA VISCOSIDAD DE UN EXCIPIENTE SELECCIONADO DEL GRUPO QUE CONSISTE DE LA N-ACETIL ARGININA, N-ACETIL LISINA, N-ACETIL PROLINA Y MEZCLAS DE LOS MISMOS EN COMBINACIÓN CON UNA PROTEÍNA TERAPÉUTICA. TAMBIÉN SE PROPORCIONA UNA FORMULACIÓN FARMACÉUTICA ESTABLE.</p>
CL2017000984A 2014-10-23 2017-04-20 Reducción de la viscosidad de formulaciones farmacéuticas CL2017000984A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462067637P 2014-10-23 2014-10-23

Publications (1)

Publication Number Publication Date
CL2017000984A1 true CL2017000984A1 (es) 2018-01-05

Family

ID=54427875

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017000984A CL2017000984A1 (es) 2014-10-23 2017-04-20 Reducción de la viscosidad de formulaciones farmacéuticas
CL2019002190A CL2019002190A1 (es) 2014-10-23 2019-08-02 Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019002190A CL2019002190A1 (es) 2014-10-23 2019-08-02 Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)

Country Status (17)

Country Link
US (2) US11813328B2 (es)
EP (2) EP3209332B1 (es)
JP (3) JP2017531682A (es)
KR (1) KR102534017B1 (es)
CN (2) CN114569716A (es)
AU (2) AU2015335743B2 (es)
BR (1) BR112017008125B1 (es)
CA (1) CA2964786C (es)
CL (2) CL2017000984A1 (es)
EA (3) EA033444B1 (es)
ES (1) ES2964713T3 (es)
IL (2) IL287947B2 (es)
MA (1) MA54716A (es)
MX (2) MX2017005243A (es)
SG (1) SG11201703152RA (es)
WO (1) WO2016065181A1 (es)
ZA (1) ZA201702762B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA033444B1 (ru) 2014-10-23 2019-10-31 Amgen Inc Снижение вязкости фармацевтических составов
JP7275027B2 (ja) * 2016-10-06 2023-05-17 アムジェン インコーポレイテッド 粘度低下タンパク質医薬製剤
JP7377596B2 (ja) * 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
MA48461A (fr) 2017-04-28 2020-03-04 Amgen Inc Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation
US12103979B2 (en) * 2017-04-28 2024-10-01 Amgen Inc. N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
CN116898955A (zh) * 2017-09-22 2023-10-20 旭化成制药株式会社 稳定性优异的含有特立帕肽的液态药物组合物
WO2019106206A1 (en) 2017-12-01 2019-06-06 Fyb 202 Project Gmbh Stable, low viscosity, high concentration liquid formulations of an anti-il-12/23p40 antibody
CA3105256A1 (en) 2018-07-05 2020-01-09 Bayer Aktiengesellschaft Novel stable high-concentration formulation for anti-fxia antibodies
EP3628683A1 (en) * 2018-09-28 2020-04-01 Zealand Pharma A/S Formulations of glucagon-like-peptide-2 (glp-2) analogues
EP3958840A1 (en) * 2019-04-23 2022-03-02 Amgen Inc. The use of low molecular weight polyvinylpyrrolidone (pvp) to reduce viscosity of high concentration protein formulations

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078997A (en) 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
WO1999024063A1 (en) 1997-11-07 1999-05-20 Chiron Corporation Compositions providing for increased igf-i solubility
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6159485A (en) * 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
AU4458401A (en) 2000-03-31 2001-10-15 Kirin Brewery Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
PL209928B1 (pl) 2000-11-07 2011-11-30 Novartis Vaccines & Diagnostic Kompozycja farmaceutyczna zawierająca biologicznie aktywny IFN-β i mannitol, wstępnie napełniona strzykawka zawierająca tę kompozycję oraz sposób wytwarzania preparatu IFN-β
NZ531211A (en) 2001-08-23 2007-04-27 Genmad As Human antibodies specific for interleukin 15 (IL-15)
JP4583762B2 (ja) 2002-02-27 2010-11-17 イミュネックス・コーポレーション ポリペプチド製剤
AU2003293543A1 (en) 2002-12-13 2004-07-09 Abgenix, Inc. System and method for stabilizing antibodies with histidine
JP2006516636A (ja) 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド 抗インテグリンαｖβ３抗体製剤及びその用途
HUE030579T2 (en) 2003-04-04 2017-05-29 Genentech Inc High Concentration Antibody And Protein Products
US8084032B2 (en) 2004-01-21 2011-12-27 Ajinomoto Co., Inc. Purification method which prevents denaturation of an antibody
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US7906625B2 (en) 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
AR064333A1 (es) 2006-12-14 2009-04-01 Schering Corp Anticuerpo anti-tslp de diseno
EP2170957A1 (en) 2007-06-20 2010-04-07 Irm, Llc Methods and compositions for treating allergic diseases
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
SG10201604258YA (en) * 2007-11-30 2016-07-28 Abbvie Biotechnology Ltd Anti-tnf antibody formulations
NZ586828A (en) * 2008-01-15 2012-12-21 Abbott Gmbh & Co Kg Powdered antibody compositions and methods of making same
TWI516501B (zh) 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP2011067202A (ja) * 2009-08-31 2011-04-07 Sanyo Chem Ind Ltd タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及びタンパク質の安定化方法
EP2501367B1 (en) * 2009-11-17 2015-01-21 Ipsen Pharma S.A.S. Formulation for HGH and RHIGF-1 combination
PL2531218T3 (pl) * 2010-02-04 2019-05-31 Csl Behring Ag Preparat immunoglobuliny
CN107693791B (zh) * 2010-02-26 2022-06-07 诺沃—诺迪斯克有限公司 包含稳定抗体的组合物
US20130171128A1 (en) * 2010-03-02 2013-07-04 Amgen Inc. Reducing viscosity of pharmaceutical formulations
JP2013525484A (ja) * 2010-05-03 2013-06-20 ジェネンテック， インコーポレイテッド タンパク質含有製剤の粘度を低減させるために有用な組成物及び方法
AR083495A1 (es) 2010-10-22 2013-02-27 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
BR112014010186A2 (pt) * 2011-10-28 2017-05-02 Integritybio Inc formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
WO2013186230A1 (en) 2012-06-12 2013-12-19 Boehringer Ingelheim International Gmbh Pharmaceutical formulation for a therapeutic antibody
US20150004174A1 (en) 2013-06-28 2015-01-01 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
TWI694836B (zh) 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物
EA033444B1 (ru) 2014-10-23 2019-10-31 Amgen Inc Снижение вязкости фармацевтических составов
EP3226895B1 (en) 2014-12-03 2020-07-22 CSL Behring AG Pharmaceutical product with increased stability comprising immunoglobulins
IL307684A (en) 2016-09-29 2023-12-01 Amgen Inc Low viscosity antigen binding proteins and methods for their preparation
JP7275027B2 (ja) 2016-10-06 2023-05-17 アムジェン インコーポレイテッド 粘度低下タンパク質医薬製剤
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法

Also Published As

Publication number Publication date
EA033444B1 (ru) 2019-10-31
CA2964786C (en) 2023-10-17
CN107206070A (zh) 2017-09-26
US20240066124A1 (en) 2024-02-29
AU2021200990B2 (en) 2023-02-16
EA201991447A1 (ru) 2019-11-29
AU2021200990A1 (en) 2021-03-11
EP3209332A1 (en) 2017-08-30
BR112017008125B1 (pt) 2023-11-21
ES2964713T3 (es) 2024-04-09
US20170333559A1 (en) 2017-11-23
JP6965321B2 (ja) 2021-11-10
EP3209332B1 (en) 2021-05-26
EP3909611B1 (en) 2023-08-30
KR20170071518A (ko) 2017-06-23
BR112017008125A2 (pt) 2018-06-19
EP3909611A1 (en) 2021-11-17
AU2015335743A1 (en) 2017-05-04
CN107206070B (zh) 2022-01-18
IL251726A0 (en) 2017-06-29
MX2021015789A (es) 2022-01-27
EA202191513A1 (ru) 2021-11-30
WO2016065181A1 (en) 2016-04-28
CA2964786A1 (en) 2016-04-28
CL2019002190A1 (es) 2019-11-22
EA201790787A1 (ru) 2017-08-31
KR102534017B1 (ko) 2023-05-19
AU2015335743B2 (en) 2020-12-24
CN114569716A (zh) 2022-06-03
IL287947B1 (en) 2024-04-01
MA54716A (fr) 2021-11-17
EA038462B1 (ru) 2021-08-31
JP7411615B2 (ja) 2024-01-11
JP2017531682A (ja) 2017-10-26
IL251726B (en) 2021-12-01
MX2017005243A (es) 2017-08-18
SG11201703152RA (en) 2017-05-30
JP2020037559A (ja) 2020-03-12
IL287947A (en) 2022-01-01
ZA201702762B (en) 2022-12-21
JP2022009223A (ja) 2022-01-14
US11813328B2 (en) 2023-11-14
IL287947B2 (en) 2024-08-01

Similar Documents

Publication Publication Date Title
CL2017000984A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas
CL2023001909A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CL2018001488A1 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
CL2017002727A1 (es) Composiciones de ácido obeticólico y métodos de uso
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2014001865A1 (es) Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer.
CR20150263A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
UY35351A (es) Formulaciones acuosas estables de adalimumab
CR20160425A (es) Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
CL2015002692A1 (es) Novedosos compuestos de bencenosulfonamida, método para sintetizarlos y uso de los compuestos en medicina y en cosméticos.
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
CL2015002897A1 (es) Inhibidores de bace1
CY1125033T1 (el) Σκευασμα μεθοτρεξατης
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
ES2552754T1 (es) Formulaciones de daptomicina y usos de la misma
CR20160002A (es) Formulación estable líquida de etelcalcetide (amg 461)